Jesper Fleischer

Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes. / Hansen, Christian Stevns; Frandsen, Christian Seerup; Fleischer, Jesper; Vistisen, Dorte; Holst, Jens Juul; Tarnow, Lise; Knop, Filip Krag; Madsbad, Sten; Andersen, Henrik Ullits; Dejgaard, Thomas Fremming.

I: Frontiers in Endocrinology, Bind 10, 242, 12.04.2019.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Hansen, CS, Frandsen, CS, Fleischer, J, Vistisen, D, Holst, JJ, Tarnow, L, Knop, FK, Madsbad, S, Andersen, HU & Dejgaard, TF 2019, 'Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes', Frontiers in Endocrinology, bind 10, 242. https://doi.org/10.3389/fendo.2019.00242

APA

Hansen, C. S., Frandsen, C. S., Fleischer, J., Vistisen, D., Holst, J. J., Tarnow, L., Knop, F. K., Madsbad, S., Andersen, H. U., & Dejgaard, T. F. (2019). Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes. Frontiers in Endocrinology, 10, [242]. https://doi.org/10.3389/fendo.2019.00242

CBE

Hansen CS, Frandsen CS, Fleischer J, Vistisen D, Holst JJ, Tarnow L, Knop FK, Madsbad S, Andersen HU, Dejgaard TF. 2019. Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes. Frontiers in Endocrinology. 10:Article 242. https://doi.org/10.3389/fendo.2019.00242

MLA

Vancouver

Hansen CS, Frandsen CS, Fleischer J, Vistisen D, Holst JJ, Tarnow L o.a. Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes. Frontiers in Endocrinology. 2019 apr 12;10. 242. https://doi.org/10.3389/fendo.2019.00242

Author

Hansen, Christian Stevns ; Frandsen, Christian Seerup ; Fleischer, Jesper ; Vistisen, Dorte ; Holst, Jens Juul ; Tarnow, Lise ; Knop, Filip Krag ; Madsbad, Sten ; Andersen, Henrik Ullits ; Dejgaard, Thomas Fremming. / Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes. I: Frontiers in Endocrinology. 2019 ; Bind 10.

Bibtex

@article{1ace11bd1fd545c78c186db02c2f5c3e,
title = "Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes",
abstract = "The role of the autonomic nervous system in the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in patients with type 1 diabetes is unknown. We assessed the association between autonomic function and weight loss induced by the GLP-1 RA liraglutide.Methods: Lira-1 was a randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of 1.8 mg liraglutide once-daily for 24 weeks in overweight patients with type 1 diabetes. Autonomic function was assessed by heart rate response to deep breathing (E/I ratio), to standing (30/15 ratio), to the Valsalva maneuver and resting heart rate variability (HRV) indices. Associations between baseline the cardiovascular autonomic neuropathy (CAN) diagnosis (> 1 pathological non-resting test) and levels of test outcomes on liraglutide-induced weight loss was assessed by linear regression models.Results: Ninety-nine patients with mean age 48 (SD 12) years, HbA(1c) 70 (IQR 66;75) mmol/mol and BMI of 30 (SD 3) kg/m(2) were assigned to liraglutide (N = 50) or placebo (N = 49). The CAN diagnosis was not associated with weight loss. A 50% higher baseline level of the 30/15 ratio was associated with a larger weight reduction by liraglutide of -2.65 kg during the trial (95% CI: -4.60; -0.69; P = 0.009). Similar significant associations were found for several HRV indices.Conclusions: The overall CAN diagnosis was not associated with liraglutide-induced weight loss in overweight patients with type 1 diabetes. Assessed separately, better outcomes for several CAN measures were associated with higher weight loss, indicating that autonomic involvement in liraglutide-induced weight loss may exist.",
keywords = "liraglutide, autonomic neuropathy, weight loss, insulin requirements, type 1 diabetes, GLUCAGON-LIKE PEPTIDE-1, DOUBLE-BLIND, FOOD-INTAKE, HEART-RATE, NEUROPATHY, GLP-1, EFFICACY, SAFETY, METABOLISM, RECEPTORS",
author = "Hansen, {Christian Stevns} and Frandsen, {Christian Seerup} and Jesper Fleischer and Dorte Vistisen and Holst, {Jens Juul} and Lise Tarnow and Knop, {Filip Krag} and Sten Madsbad and Andersen, {Henrik Ullits} and Dejgaard, {Thomas Fremming}",
year = "2019",
month = apr,
day = "12",
doi = "10.3389/fendo.2019.00242",
language = "English",
volume = "10",
journal = "Frontiers in Endocrinology",
issn = "1664-2392",
publisher = "Frontiers Media S.A",

}

RIS

TY - JOUR

T1 - Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes

AU - Hansen, Christian Stevns

AU - Frandsen, Christian Seerup

AU - Fleischer, Jesper

AU - Vistisen, Dorte

AU - Holst, Jens Juul

AU - Tarnow, Lise

AU - Knop, Filip Krag

AU - Madsbad, Sten

AU - Andersen, Henrik Ullits

AU - Dejgaard, Thomas Fremming

PY - 2019/4/12

Y1 - 2019/4/12

N2 - The role of the autonomic nervous system in the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in patients with type 1 diabetes is unknown. We assessed the association between autonomic function and weight loss induced by the GLP-1 RA liraglutide.Methods: Lira-1 was a randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of 1.8 mg liraglutide once-daily for 24 weeks in overweight patients with type 1 diabetes. Autonomic function was assessed by heart rate response to deep breathing (E/I ratio), to standing (30/15 ratio), to the Valsalva maneuver and resting heart rate variability (HRV) indices. Associations between baseline the cardiovascular autonomic neuropathy (CAN) diagnosis (> 1 pathological non-resting test) and levels of test outcomes on liraglutide-induced weight loss was assessed by linear regression models.Results: Ninety-nine patients with mean age 48 (SD 12) years, HbA(1c) 70 (IQR 66;75) mmol/mol and BMI of 30 (SD 3) kg/m(2) were assigned to liraglutide (N = 50) or placebo (N = 49). The CAN diagnosis was not associated with weight loss. A 50% higher baseline level of the 30/15 ratio was associated with a larger weight reduction by liraglutide of -2.65 kg during the trial (95% CI: -4.60; -0.69; P = 0.009). Similar significant associations were found for several HRV indices.Conclusions: The overall CAN diagnosis was not associated with liraglutide-induced weight loss in overweight patients with type 1 diabetes. Assessed separately, better outcomes for several CAN measures were associated with higher weight loss, indicating that autonomic involvement in liraglutide-induced weight loss may exist.

AB - The role of the autonomic nervous system in the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in patients with type 1 diabetes is unknown. We assessed the association between autonomic function and weight loss induced by the GLP-1 RA liraglutide.Methods: Lira-1 was a randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of 1.8 mg liraglutide once-daily for 24 weeks in overweight patients with type 1 diabetes. Autonomic function was assessed by heart rate response to deep breathing (E/I ratio), to standing (30/15 ratio), to the Valsalva maneuver and resting heart rate variability (HRV) indices. Associations between baseline the cardiovascular autonomic neuropathy (CAN) diagnosis (> 1 pathological non-resting test) and levels of test outcomes on liraglutide-induced weight loss was assessed by linear regression models.Results: Ninety-nine patients with mean age 48 (SD 12) years, HbA(1c) 70 (IQR 66;75) mmol/mol and BMI of 30 (SD 3) kg/m(2) were assigned to liraglutide (N = 50) or placebo (N = 49). The CAN diagnosis was not associated with weight loss. A 50% higher baseline level of the 30/15 ratio was associated with a larger weight reduction by liraglutide of -2.65 kg during the trial (95% CI: -4.60; -0.69; P = 0.009). Similar significant associations were found for several HRV indices.Conclusions: The overall CAN diagnosis was not associated with liraglutide-induced weight loss in overweight patients with type 1 diabetes. Assessed separately, better outcomes for several CAN measures were associated with higher weight loss, indicating that autonomic involvement in liraglutide-induced weight loss may exist.

KW - liraglutide

KW - autonomic neuropathy

KW - weight loss

KW - insulin requirements

KW - type 1 diabetes

KW - GLUCAGON-LIKE PEPTIDE-1

KW - DOUBLE-BLIND

KW - FOOD-INTAKE

KW - HEART-RATE

KW - NEUROPATHY

KW - GLP-1

KW - EFFICACY

KW - SAFETY

KW - METABOLISM

KW - RECEPTORS

U2 - 10.3389/fendo.2019.00242

DO - 10.3389/fendo.2019.00242

M3 - Journal article

C2 - 31031712

VL - 10

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

SN - 1664-2392

M1 - 242

ER -